Nicox NCX 470 glaucoma NDA accepted with April 2027 PDUFA date
Nicox has confirmed that the US Food and Drug Administration has accepted the New Drug Application for NCX 470 and set 30 April 2027 as the PDUFA target date for a review decision. The NDA was filed on 30 June 2026 by Kowa, Nicox's exclusive US licensee, on the basis of results from the Mont Blanc and Denali Phase 3 trials. FDA acceptance of the filing confirms the dossier is sufficiently complete for formal review, and does not constitute approval.
NCX 470, known scientifically as bimatoprost grenod, combines bimatoprost, a well-established prostaglandin analogue, with a nitric oxide-donating moiety in a single molecule. The company says the dual mechanism is designed to lower intraocular pressure (IOP) via two complementary pathways: prostaglandin-mediated uveoscleral outflow and nitric oxide-driven enhancement of aqueous humour drainage through the trabecular meshwork. In the Mont Blanc and Denali trials, NCX 470 achieved IOP reductions of up to 10 mmHg with what the company described as a favourable safety profile.
Commercialisation pathway
Nicox has filed NDAs in two markets concurrently. A submission in China was made in August 2026, with Ocumension Therapeutics holding the licence for the Chinese, Korean and South-East Asian markets. Kowa covers the rest of the world. Chief executive Gavin Spencer said that, subject to regulatory approval, both partners have "established commercial organisations in place to support launch of NCX 470 swiftly after approval is granted." A US approval would trigger a milestone payment to Nicox, with royalties on net sales providing a recurring revenue stream thereafter.
A separate Phase 3 programme in Japan is ongoing, adding a third potential market to the regulatory dossier, though no PDUFA-equivalent date has been disclosed for that jurisdiction.
Market context
Glaucoma is a large and competitive ophthalmology market. Prostaglandin analogues, including bimatoprost itself (already marketed as Lumigan by AbbVie), dominate first-line IOP management. The rationale for NCX 470 rests on whether the added nitric oxide component delivers clinically meaningful additional IOP reduction over existing prostaglandin monotherapy, particularly for patients who do not reach target pressure on standard drops.
Nicox is not the only company exploring nitric oxide pathways in glaucoma. Bausch + Lomb's Vyzulta, which is also a nitric oxide-donating latanoprost prodrug and notably Nicox's own first licensed product, has been commercially available in the US since 2017. The presence of Vyzulta in the market means that NCX 470 will need to demonstrate differentiation not only versus plain bimatoprost but also versus an already-approved NO-donating comparator. Kowa's sales infrastructure and any positioning on clinical superiority data will be central to its launch narrative.
For Nicox itself, approval would represent a meaningful shift in its revenue profile. The company currently generates licensing income from Vyzulta, licensed exclusively to Bausch + Lomb, and from Zerviate in allergic conjunctivitis. A royalty stream on NCX 470 US and China sales would add a third commercial pillar for the Sophia Antipolis-based company, which is listed on Euronext Growth Paris. Investors will be focused on whether the FDA raises any substantive clinical or manufacturing queries during the review period and on readout timing in China, where the regulatory calendar is less predictable than the US PDUFA framework.